What is the current focus at Novartis?
Right now, the focus is about 80 per cent innovative medicines and 20 per cent generics. It is a good mix of long-term and short-term. We have 15 launches coming up in innovative medicines. That, I think, is the highest in the industry. We got six new drug approvals last year. We have 165 projects in drug development, which will hopefully be the next wave of innovation at Novartis. It’s the right balance.
Some of this technology will take longer to evolve. Some of them are near-term RNA interference, and to some extent cell therapy and gene therapy. But in the longer term, we will need these technologies to mature. So this will be a 5-10-year journey. We try to balance as we need short-term launches to keep driving the company’s growth.
What are the changes taking place in the company?
We’ve been on a journey to focus as a medicine company powered by data science and digital technologies. I’ve successfully integrated a company that’s 100 per cent focused on medicines. Its footprint is geographically diverse, and is also present across 10 therapeutic areas and different technology platforms. We continue to have traditional platforms, small molecule and large molecule drugs, but also new platforms like cell and gene therapies. We want to transform to the next level of performance using data science and digital technologies.
This story is from the March 22, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 22, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
PMS Vs MF The Big Fight
How do mutual funds and portfolio management services match up? Know the score on structure, rules, entry fees, charges, and tax perks to pick the right path for your financial journey
Four Levers Of Enterprise AI Strategy
Wide-scale private sector AI deployment and new AI-based business opportunities and ecosystems can truly supercharge the Indian economy
"Don't let a unique chance slip by"
JEFF MAGGIONCALDA | CHIEF EXECUTIVE OFFICER | COURSERA
THE INCOMING DISRUPTION
The disruption in the industrial sector is still unknown, but inevitable. Companies need to wake up
THE WHEEL WHISPERER
For Manan Shah, Managing Director of MICL Group, luxury cars are not about showcasing one's wealth or status. It is about personal well-being
TRIPPING WITH TECH
A road trip is an adventure like no other. While you take in the experience, get some peace of mind with these nifty gadgets
Transforming Spaces
WHETHER YOU WANT TO REDECORATE YOUR BEDROOM OR HALLWAY, A GORGEOUS WALLPAPER ADDS FLAIR TO YOUR HOME AND ALLOWS YOU TO STAMP YOUR STYLE IN YOUR NEW ABODE
ALPHATALE
MONEY MANAGERS TO THE AFFLUENT DELIVERED ROBUST RETURNS TO INVESTORS IN THE PAST YEAR, THANKS TO THE BUOYANCY IN THE MARKETS. BUSINESS TODAY DECODES THEIR STRATEGY
"THE ALTERNATIVES SPACE CAN GROW 3X IN FIVE YEARS"
Vikaas M. Sachdeva, MD of Sundaram Alternates, talks about where India's alternative investment industry is headed
"ALWAYS BE DATA-DRIVEN WHILE INVESTING"
First Global's Founder and CMD Devina Mehra on her company's PMS outperformance, technology and industry
